A predictive model for the detection of tumor lysis syndrome during AML induction therapy

Leukemia and Lymphoma

Volumn 47, Issue 5, 2006, Pages 877-883

  Mato, Anthony R ^a   Riccio, Brett E ^b   Qin, Li ^c   Heitjan, Daniel F ^a   Carroll, Martin ^a   Loren, Alison ^a   Porter, David L ^a   Perl, Alexander ^a   Stadtmauer, Edward ^a   Tsai, Donald ^a   Gewirtz, Alan ^a   Luger, Selina M ^a,d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute myeloid leukemia; Acute renal failure; Hyperuricemia; Tumor lysis syndrome; Urate nephropathy

Indexed keywords

ALLOPURINOL; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; RETINOIC ACID; TOPOTECAN; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MANAGEMENT; FEMALE; GENDER; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MODEL; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COHORT STUDIES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR LYSIS SYNDROME;

EID: 33744924241     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500404662     Document Type: Article

References (24)

1. Cohen, L and Balow, J and Magrath, I and Poplack, D and Ziegler, J. (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma Am J Med, 68, pp. 486-491.
2. Flombaum, C. (2000) Metabolic emergencies in the cancer patient Semin Oncol, 27, pp. 322-334.
3. Arrambide, K and Toto, R. (1993) Tumor lysis syndrome Semin Nephrol, 13, pp. 273-280.
4. Conger, J and Falk, S and Guggenheim, S and Burke, T. (1976) A micropuncture study of the early phase of acute urate nephropathy J Clin Invest, 58, pp. 681-689.
5. Jeha, S. (2001) Tumor lysis syndrome Semin Hematol, 38(Suppl 10), pp. 4-8.
6. Chasty, R and Liu-Yin, J. (1993) Acute tumour lysis syndrome Br J Hosp Med, 49, pp. 488-492.
7. Seftel, M and Bruyere, H and Copland, M and Hogge, D and Horsman, D and Nantel, S and (2002) Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22) Eur J Haematol, 69, pp. 193-199.
8. Annemans, L and Moeremans, K and Lamotte, M and Garcia Conde, J and van den Berg, H and Myint, H and (2003) Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries Leuk Lymphoma, 44, pp. 77-83.
9. Razis, E and Arlin, Z and Ahmed, T and Feldman, E and Puccio, C and Cook, P and (1994) Incidence and treatment of tumor lysis syndrome in patients with acute leukemia Acta Haematol, 91, pp. 171-174.
10. Lotfi, M and Brandwein, J. (1998) Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature Leuk Lymphoma, 29, pp. 625-628.
11. Anderson, S and Files, J. (2002) Tumor lysis syndrome secondary to Gemtuzumab Ozogamicin in a patient with acute myelogenous leukemia J Miss State Med Assoc, 43, pp. 105-106.
12. Kikuchi, T and Miyata, A and Fujii, S and Kikuchi, T. (2003) Acute myelogenous leukemia complicated with severe tumor lysis syndrome after a single day of idarubicin/cytarabine chemotherapy Rinsho Ketsueki, 44, pp. 1113-1116.
13. Seki, J and Al-Omar, H and Amato, D and Sutton, D. (2003) Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia Ann Pharmacother, 37, pp. 675-678.
14. Hanley, J and McNeil, B. (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology, 143, pp. 29-36.
15. DeLong, E and DeLong, D and Clarke-Pearson, D. (1998) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach Biometrics, 44, pp. 837-845.
16. Harrell, F and Lee, K and Mark, D. (1996) Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med, 15, pp. 361-387.
17. Jekel, J and Elmore, J and Katz, D. (1996) Epidemiology, Biostatisitcs, and Preventive Medicine. Philadelphia PA: WB Saunders.
18. Al-Bahar, S and Pandita, R and Dhabhar, B and Al-Bahar, E. (1994) Acute tumor lysis syndrome in acute lymphoblastic leukemia and Burkitt's lymphoma: Experience in a single centre in Kuwait Ann Oncol, 5, pp. 379.
19. Wossmann, W and Schrappe, M and Meyer, U and Zimmermann, M and Reiter, A. (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase Ann Hematol, 82, pp. 160-165.
20. Cairo, M and Bishop, M. (2004) Tumour lysis syndrome: New therapeutic strategies and classification Br J Haematol, 127, pp. 3-11.
21. Justice, A and Covinsky, K and Berlin, J. (1999) Assessing the generalizability of prognostic information Ann Intern Med, 130, pp. 515-512.
22. Fang, J and Alderman, M. (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey JAMA, 283, pp. 2404-2410.
23. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med, 329, pp. 987-994.
24. Efron, B and Tibshirani, R. (1994) An Introduction to the Bootstrap. London: CRC Press.